|
|
|
|
|
FREMONT, CA, 2023年3月28日 - (亞太商訊) - Q'Apel Medical Inc. was granted the CE Mark under MDR for Walrus, their U.S. market-leading Balloon Guide Catheter (BGC) utilized in treating patients suffering an acute ischemic stroke. The Walrus BGC has been utilized by Neuro Interventional physicians since 2019 and has successfully treated over 20,000 patients in the United States.
The Walrus BGC is a unique development in the field of Mechanical Thrombectomy procedures. It provides physicians with not only the known benefits of BGC use clinically, but unique to Walrus, superior ease of use in preparation in these urgent procedures. Importantly, Walrus enables the physicians to navigate the catheter into a more distal location easily and safely compared to other systems, which is associated with improved patient outcomes from stroke.
"The anticipation of Walrus in our international markets has been enormous, and we look forward to the same performance and loyalty around Walrus we have been fortunate to experience in the United States," said King Nelson, Q'Apel Medical's CEO.
"We are thrilled to be entering the EU and other international markets with Walrus and providing more physicians in more countries the unparalleled performance of our flagship catheter. This CE Mark certification represents a significant growth milestone for Q'Apel Medical providing access to new markets," commented Jodie Fam, Chief Marketing Officer & GM International.
About Q'Apel Medical
Q'Apel Medical designs highly innovative technologies for neurovascular interventions and unmet clinical needs. Q'Apel's portfolio comprises three products, the Walrus Balloon Catheter System, the Wahoo Hybrid Access System and Armadillo Radial Access System. Before Walrus came along, balloon-based variable stiffness catheters brought all manner of technological constraints. Not anymore. By blending flow control, trackability, support, and access into one revolutionary solution, Walrus offers truly unmatched functionality. The Wahoo Hybrid Access System and Armadillo Radial Access System are dual-mode catheters and part of the SelectFlex(TM) Family of Neurovascular Catheters. These devices feature two distinct operational modes, allowing physicians to easily switch modes at any point during a clinical case and reducing the need for multiple catheters in challenging procedures.
Media Contact:
Jodie Fam
415 244 9885
+44 7500702108
jfam@qapelmedical.com
info@qapelmedical.com
www.qapelmedical.com
Contact Information
Jodie Fam
Chief Marketing Officer & GM International
jfam@qapelmedical.com
4152449885
SOURCE: Q'Apel Medical Inc.
話題 Press release summary
部門 制药及生物技术, 健康与医药
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network
|
|
|
|
|
|
 |
|
Latest Press Releases
Philippine Airlines' Flash Sale Offers Up to 40% Off Base Fares Until July 17 Only 
July 17, 2026, 13:48 HKT/SGT
|
|
|
Riyadh Emerges as a Global Powerhouse as Blockchain Infrastructure & AI Take Center Stage at Global Blockchain Show 2026
July 17, 2026, 12:58 HKT/SGT
|
|
|
AI-Driven LiveOps and Mobile Dominance Take Center Stage at Global Games Show Riyadh 2026
July 17, 2026, 12:14 HKT/SGT
|
|
|
JCB Celebrates 30 Years of Trust, Honoring 70 Years of Japan-Philippines Friendship
Friday, July 17, 2026 9:00:00 AM
|
|
|
CTF Life Becomes First Insurer to Forge Long-term Strategic Partnership with Tencent Music Entertainment Group to Debut TIMA in Hong Kong This August
July 17, 2026, 08:27 HKT/SGT
|
|
|
TANAKA Commences Operation of "TANAKA H2 Nexus", One of Japan's Largest 500 kW Pure Hydrogen Fuel Cell Power Generation Facilities
Thursday, July 16, 2026 9:00:00 PM
|
|
|
Community Creates Mega Artwork for HKTDC 60th Anniversary
July 16, 2026, 19:15 HKT/SGT
|
|
|
Cornerstone Robotics to Present at the 2nd Global Health Summit (GHS 2026)
July 16, 2026, 14:07 HKT/SGT
|
|
|
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Wednesday, July 15, 2026 11:18:00 PM
|
|
|
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
Wednesday, July 15, 2026 10:51:00 PM
|
|
|
|
|
More Press release >> |
|
|
|
